[Value of the combination of 4-aminoquinoline and sulfamethoxypyridazine in treatment of the tuberculoid form of Hansen's disease. Results obtained after 5 years of observation].
D000328:Adult; D000962:Antimalarials / Q000627:therapeutic use*; D003622:Dapsone / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D003937:Diagnosis, Differential; D004357:Drug Synergism; D006801:Humans; D007918:Leprosy / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D011804:Quinolines / Q000627:therapeutic use*; D013421:Sulfamethoxypyridazine / Q000627:therapeutic use*; D013997:Time Factors; D014382:Tuberculosis, Cutaneous / Q000175:diagnosis
D000962:Antimalarials; D003692:Delayed-Action Preparations; D011804:Quinolines; D003622:Dapsone; D013421:Sulfamethoxypyridazine
Intérêt de l'association de l'amino-4 quinoléine et de la sulfaméthoxy-pyridazine dans le traitement de la maladie de Hansen, forme tuberculoide. Résultats obtenus après cinq ans d'observation.